Literature DB >> 1686953

Demonstration of glomerular DPP IV activity in kidney diseases.

D Stiller1, H Bahn, C August.   

Abstract

Dipeptidylpeptidase IV (DPP IV) activity has been found in glomeruli of the rat and other previously investigated animal species, but has not been detected in the glomeruli of the normal human kidney. Under pathological conditions, enzyme activity may be registered. Following investigations on 155 human renal biopsies using polyclonal antisera against IgG, IgA, IgM, C3C, Fibrinogen, and DPP IV, we found glomerular enzyme activity in 43 cases of various histological diagnoses, but never in normal renal tissue. Identical results could be found by the Gly-Prol-beta-MNA substrate reaction. The localization of glomerular enzyme activity in capillary walls could not be definitely determined, possibly enzyme activity occurs in podocytes. Correlation of glomerular DPP IV activity to the deposition of immunoglobulins was not found. Nevertheless, the appearance of DPP IV in human glomeruli seems to be in correlation with some clinical findings, e.g. hypertension. The importance of DPP IV activity in pathohistologically changed glomeruli of human kidney is definitely large, but needs further investigation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686953     DOI: 10.1016/S0065-1281(11)80302-8

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  7 in total

Review 1.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

2.  Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial.

Authors:  Mohammad Amin Mohammad Zadeh Gharabaghi; Mohammad Reza Rezvanfar; Nasser Saeedi; Faezeh Aghajani; Mohammad Alirezaei; Pourya Yarahmadi; Amin Nakhostin-Ansari
Journal:  Clin Diabetes Endocrinol       Date:  2022-05-25

3.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

4.  Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.

Authors:  Luca Musante; Dorota Tataruch; Dongfeng Gu; Xinyu Liu; Carol Forsblom; Per-Henrik Groop; Harry Holthofer
Journal:  J Diabetes Res       Date:  2015-03-19       Impact factor: 4.011

5.  Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Authors:  Per-Henrik Groop; Mark E Cooper; Vlado Perkovic; Berthold Hocher; Keizo Kanasaki; Masakazu Haneda; Guntram Schernthaner; Kumar Sharma; Robert C Stanton; Robert Toto; Jessica Cescutti; Maud Gordat; Thomas Meinicke; Audrey Koitka-Weber; Sandra Thiemann; Maximilian von Eynatten
Journal:  Diabetes Obes Metab       Date:  2017-07-31       Impact factor: 6.577

Review 6.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

7.  Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.

Authors:  Hiroki Teragawa; Takeshi Morimoto; Yuichi Fujii; Tomohiro Ueda; Mio Sakuma; Michio Shimabukuro; Osamu Arasaki; Koichi Node; Takashi Nomiyama; Shinichiro Ueda
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-03       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.